多发性骨髓瘤相关生物标志物的研究进展

doi:10.16150/j.1671-2870.2021.05.016

摘要/Abstract

中图分类号:

R735

赵建治, 糜坚青. 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021, 20(05): 507-511.

图/表 3

参考文献 30

[1]	Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis[J]. Front Oncol, 2020,9:1513. doi: 10.3389/fonc.2019.01513 URL
[2]	Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients[J]. Leukemia, 2014,28(5):1122-1128. doi: 10.1038/leu.2013.313 pmid: 24157580
[3]	Cohen AD. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update[J]. Am Soc Clin Oncol Educ Book, 2018,38:e6-e15.
[4]	Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group[J]. J Clin Oncol, 2015,33(26):2863-2869. doi: 10.1200/JCO.2015.61.2267
[5]	Ong SY, de Mel S, Chen YX, et al. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group[J]. Bone Marrow Transplant, 2016,51(7):933-937. doi: 10.1038/bmt.2016.43 URL
[6]	Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study[J]. J Clin Oncol,2017, 35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975 URL
[7]	Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma[J]. Blood, 2017,130(1):30-34. doi: 10.1182/blood-2017-03-774422 pmid: 28432222
[8]	Özkurt ZN, Sucak GT, Akı ŞZ, et al. Early prognostic value of monitoring serum free light chain in patients with multiple myeloma undergoing autologous stem cell transplantation[J]. Cancer Invest, 2017,35(3):195-201. doi: 10.1080/07357907.2016.1270958 URL
[9]	李璐, 姜华, 傅卫军, 等. 血清游离轻链比值及差值对初诊多发性骨髓瘤患者预后价值的评估与比较[J]. 中华血液学杂志, 2019,40(4):321-326.
[10]	Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report[J]. Cancer Res, 2004,64(4):1546-1558. pmid: 14989251
[11]	Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2[J]. Blood, 2011,117(18):4696-700. doi: 10.1182/blood-2010-10-300970 URL
[12]	Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)[J]. J Clin Oncol, 2010,28(30):4630-4634. doi: 10.1200/JCO.2010.28.3945 pmid: 20644101
[13]	Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients[J]. Blood Cancer J, 2014,4(3):e191. doi: 10.1038/bcj.2014.13 URL
[14]	Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood, 2007,109(6):2276-2284. doi: 10.1182/blood-2006-07-038430 pmid: 17105813
[15]	Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome[J]. Clin Cancer Res. 2010 Mar 15; 16(6):1856-64. doi: 10.1158/1078-0432.CCR-09-2831 URL
[16]	Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials[J]. J Clin Oncol, 2017,35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517 URL
[17]	Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016,17(8):e328-e346.
[18]	National Comprehensive Cancer Network.Multiple Myeloma (verson 2.2020).
[19]	Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation[J]. Blood, 2008,112(10):4017-4023.
[20]	Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma[J]. Blood, 2015,125(20):3059-3068. doi: 10.1182/blood-2014-11-568907 URL
[21]	Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia, 2014,28(2):391-397. doi: 10.1038/leu.2013.217 pmid: 23860448
[22]	Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood, 2014, 123(20):3073-3079. doi: 10.1182/blood-2014-01-550020 pmid: 24646471
[23]	Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma[J]. J Clin Oncol, 2015,33(33):3911-3920. doi: 10.1200/JCO.2014.59.1503 pmid: 26282654
[24]	Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014,6(224):224ra24.
[25]	Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma[J]. Leukemia, 2013,27(3):680-685. doi: 10.1038/leu.2012.237 pmid: 22902364
[26]	Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma[J]. Leukemia, 2014,28(10):2060-2065. doi: 10.1038/leu.2014.98 pmid: 24618735
[27]	Paiva B, Puig N, Cedena MT, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance[J]. Leukemia, 2017,31(2):382-392. doi: 10.1038/leu.2016.211 pmid: 27479184
[28]	Peceliunas V, Janiulioniene A, Matuzeviciene R, et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma[J]. Leuk Lymphoma, 2012, 53(4):641-647. doi: 10.3109/10428194.2011.627481 URL
[29]	Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates[J]. Nat Commun, 2017,8:15086. doi: 10.1038/ncomms15086 URL
[30]	Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma[J]. Leukemia, 2017,31(8):1695-1705. doi: 10.1038/leu.2016.366 pmid: 27899805

分级	ISS	R-ISS
Ⅰ	β₂微球蛋白<3.5 mg/L,且白蛋白≥35 g/L	β₂微球蛋白<3.5 mg/L,白蛋白≥35 g/L,LDH正常且没有高危细胞遗传学异常
Ⅱ	排除Ⅰ级和Ⅲ级	排除Ⅰ级和Ⅱ级
Ⅲ	β₂微球蛋白>5.5 mg/L	β₂微球蛋白>5.5 mg/L,或者LDH升高、有高危组细胞遗传学异常

遗传学异常	预后
三倍体	低危
t(11;14)
t(6;14)
-13	中危
1q扩增
t(4;14)
17p13-	高危
t(14;16)
t(14;20)

分组	遗传学异常
高危组	t(4;14); t(14;16); t(14;20); Del 17p; p53突变; Gain 1q; RISS分期3; High Plasma Cell S-phase; GEP:High risk signature 双打击MM：任何2种高危遗传学异常; 三打击MM：3个或者更多高危遗传学异常
标危组	其他类型,三倍体; t(11;14); t(6;14);

多发性骨髓瘤相关生物标志物的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	武冬冬, 陈玉辉, 刘芳, 刘银红, 蒋景文. 脑小血管疾病合并中枢神经系统退行性疾病机制的研究进展[J]. 诊断学理论与实践, 2022, 21(05): 644-649.
[2]	周思锋, 徐海舒, 范欣生. 基于不同生物样本代谢组学的OSAHS生物标志物研究进展[J]. 诊断学理论与实践, 2022, 21(04): 535-540.
[3]	李建平, 任汝静, 王刚. 阿尔茨海默病的临床诊治进展[J]. 诊断学理论与实践, 2022, 21(01): 18-21.
[4]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.
[5]	寇明坤, 徐娜娜, 石静云, 吴涛. 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(06): 588-591.
[6]	张华, 陆炜, 杨承翌, 项明洁. 血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值[J]. 诊断学理论与实践, 2021, 20(05): 462-465.
[7]	范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海. MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400.
[8]	罗婷, 周建桥. 超声新技术在预测乳腺癌分子标志物中的应用进展[J]. 诊断学理论与实践, 2020, 19(03): 325-328.
[9]	彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128.
[10]	陆弘逾, 曹亚峰, 顾俊, 王静, 陈梅, 宋陆茜. 神经电生理检查对多发性骨髓瘤患者硼替佐米治疗相关周围神经病的预测及诊断意义[J]. 诊断学理论与实践, 2019, 18(06): 640-644.
[11]	陈海燕, 杨小宝, 许大康. 新生物标志物在胃肠道肿瘤中疗效预测和预后价值的研究进展[J]. 诊断学理论与实践, 2019, 18(06): 704-710.
[12]	陈平, 吴云林. 胃癌、结肠直肠癌血清标志物在疾病筛查、诊断中的应用新进展[J]. 诊断学理论与实践, 2019, 18(04): 377-382.
[13]	罗清琼, 陈福祥. 肿瘤免疫治疗策略的转变及相关标志物研究现状[J]. 诊断学理论与实践, 2019, 18(04): 387-393.
[14]	杜坤, 杨喜, 卞炳贤, 任懿倩, 张广慧. 血清presepsin(sCD14-ST)、降钙素原、C反应蛋白和白介细胞素-6诊断血流细菌感染的诊断性能比较[J]. 诊断学理论与实践, 2018, 17(05): 581-585.
[15]	崔诗爽, 陈生弟, 王刚. 帕金森病体液生物标志物研究进展[J]. 诊断学理论与实践, 2018, 17(04): 471-476.